0.8743
price up icon1.52%   0.0143
after-market アフターアワーズ: .87 -0.0043 -0.49%
loading
前日終値:
$0.86
開ける:
$0.877
24時間の取引高:
198.46K
Relative Volume:
1.82
時価総額:
$54.90M
収益:
-
当期純損益:
$-112.67M
株価収益率:
-0.4144
EPS:
-2.11
ネットキャッシュフロー:
$-79.26M
1週間 パフォーマンス:
+2.60%
1か月 パフォーマンス:
-9.05%
6か月 パフォーマンス:
-14.40%
1年 パフォーマンス:
-25.38%
1日の値動き範囲:
Value
$0.8511
$0.92
1週間の範囲:
Value
$0.80
$0.92
52週間の値動き範囲:
Value
$0.69
$1.60

Kronos Bio Inc Stock (KRON) Company Profile

Name
名前
Kronos Bio Inc
Name
セクター
Healthcare (1196)
Name
電話
(650) 781-5200
Name
住所
1300 S. EL CAMINO REAL, SAN MATEO
Name
職員
58
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
KRON's Discussions on Twitter

KRON を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KRON 0.8743 54.90M 0 -112.67M -79.26M -2.11
VRTX 450.37 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.50 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 596.74 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.80 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.23 24.89B 3.30B -501.07M 1.03B 11.54

Kronos Bio Inc Stock (KRON) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2022-09-14 開始されました Berenberg Buy
2021-10-20 再開されました Cowen Outperform
2021-06-24 開始されました H.C. Wainwright Buy
2020-11-03 開始されました Cowen Outperform
2020-11-03 開始されました Goldman Buy
2020-11-03 開始されました Jefferies Buy
2020-11-03 開始されました Piper Sandler Overweight
すべてを表示

Kronos Bio Inc (KRON) 最新ニュース

pulisher
05:05 AM

Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals

05:05 AM
pulisher
Nov 16, 2024

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 16, 2024
pulisher
Nov 15, 2024

Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Kronos Bio shares downgraded to hold by TD Cowen - Investing.com India

Nov 15, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio (NASDAQ:KRON) Rating Lowered to "Hold" at TD Cowen - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

TD Cowen Downgrades Kronos Bio (KRON) - MSN

Nov 14, 2024
pulisher
Nov 13, 2024

Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 10, 2024

Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St

Nov 10, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 06, 2024

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Nov 02, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World

Nov 02, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 30, 2024

Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 30, 2024
pulisher
Oct 29, 2024

Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 25, 2024

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN

Oct 25, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail

Oct 23, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 09, 2024
pulisher
Oct 08, 2024

Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online

Oct 08, 2024
pulisher
Oct 08, 2024

Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire

Oct 07, 2024
pulisher
Oct 01, 2024

Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire

Oct 01, 2024
pulisher
Sep 29, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire

Sep 25, 2024
pulisher
Sep 23, 2024

Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

How the (KROS) price action is used to our Advantage - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News

Sep 23, 2024

Kronos Bio Inc (KRON) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
大文字化:     |  ボリューム (24 時間):